B细胞受体介导的NFATc1激活诱导弥漫大B细胞淋巴瘤中IL-10/STAT3/PD-L1信号传导
研究利用蛋白质组学方法和患者来源的B细胞淋巴瘤细胞系,发现BCR介导的NFATc1激活上调IL-10表达,进而激活JAK2/STAT3通路诱导PD-L1表达;BTK抑制剂可阻断该过程,并在两个原发DLBCL队列中得到验证。
要点
- BCR-NFATc1-IL-10-JAK2/STAT3轴调控非生发中心型DLBCL的PD-L1表达。
- BTK抑制剂(伊布替尼、阿卡替尼、BGB-3111)阻断NFATc1和STAT3活化,抑制IL-10和PD-L1表达。
- 在428例和350例原发DLBCL队列中验证了IL-10、STAT3与PD-L1之间的显著相关性。
核心结论
- B细胞淋巴瘤细胞中PD-L1表达受BCR和JAK2/STAT3等交互信号通路调控,小分子抑制剂可调节PD-L1表达以增强免疫治疗。
研究设计与样本
- 研究采用蛋白质组学方法和患者来源的B细胞淋巴瘤细胞系探索PD-L1表达调控机制。
- 在包含428例和350例的两个原发DLBCL队列中验证PD-L1信号网络。
主要发现
- BCR介导的NFATc1激活上调PD-L1+ B细胞淋巴瘤细胞中IL-10趋化因子表达。
- 释放的IL-10激活JAK2/STAT3通路,导致STAT3诱导的PD-L1表达。
- IL-10拮抗抗体消除IL-10/STAT3信号和PD-L1蛋白表达。
- BTK抑制剂(伊布替尼、阿卡替尼和BGB-3111)抑制BCR通路,阻断NFATc1和STAT3激活,从而抑制IL-10和PD-L1表达。
- 在428例和350例原发DLBCL队列中显示IL-10、STAT3和PD-L1之间显著相关。
临床怎么用
- 作者认为PD-L1表达可被小分子抑制剂调节以增强免疫治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Knowledge of programmed death ligand 1 (PD-L1) expression and its regulation in B-cell lymphoma cells is limited. Investigating mechanisms that control PD-L1 expression in B-cell lymphoma cells might identify biomarkers that predict the efficacy of immunotherapy with anti-programmed death-1/PD-L1 antibodies. In addition, identification of mechanisms that regulate PD-L1 may identify molecules that can be targeted to improve the clinical efficacy of immune checkpoint inhibitors. In this study, we used proteomic approaches and patient-derived B-cell lymphoma cell lines to investigate mechanisms that regulate PD-L1 expression. We found that PD-L1 expression, particularly in nongerminal center B cell-derived diffuse large B-cell lymphoma (DLBCL), is controlled and regulated by several interactive signaling pathways, including the B-cell receptor (BCR) and JAK2/STAT3 signaling pathways. We found that that BCR-mediated NFATc1 activation upregulates IL-10 chemokine expression in PD-L1+ B-cell lymphoma cells. Released IL-10 activates the JAK2/STAT3 pathway, leading to STAT3-induced PD-L1 expression. IL-10 antagonist antibody abrogates IL-10/STAT3 signaling and PD-L1 protein expression. We also found that BCR pathway inhibition by BTK inhibitors (ibrutinib, acalabrutinib, and BGB-3111) blocks NFATc1 and STAT3 activation, thereby inhibiting IL-10 and PD-L1 expression. Finally, we validated the PD-L1 signaling network in 2 primary DLBCL cohorts consisting of 428 and 350 cases and showed significant correlations among IL-10, STAT3, and PD-L1. Thus, our findings reveal a complex signaling network regulating PD-L1 expression in B-cell lymphoma cells and suggest that PD-L1 expression can be modulated by small molecule inhibitors to potentiate immunotherapies.
引用
- Li L, Zhang J, Chen J, et al. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018. PMID: 30209121. doi:10.1182/blood-2018-03-841015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。